CAJ | 학술논문

目的：观察依达拉奉治疗脑干出血的临床疗效及安全性。方法：选择急性脑干出血患者40例，随机分为依达拉奉治疗组(治疗组)20例，常规治疗组(对照组)20例。对照组给予脱水、控制血压、控制血糖、防治并发症等处理；治疗组在常规治疗基础上给予依达拉奉30 mg静脉滴注，每天2次，共14 d。2组在治疗前后进行欧洲卒中评分( ESS )、日常生活能力评分( ADL)，判断其疗效，观察其有无不良反应。结果：治疗组治疗后7 d、14 d和21 d ESS和ADL评分均明显高于对照组( P<0.01)，治疗组治疗后14 d和21 d总有效率均高于对照组(P<0.01)，且无严重不良反应。结论：依达拉奉可有效治疗脑干出血并改善预后，安全性良好。
목적：관찰의체랍봉치료뇌간출혈적림상료효급안전성。방법：선택급성뇌간출혈환자40례，수궤분위의체랍봉치료조(치료조)20례，상규치료조(대조조)20례。대조조급여탈수、공제혈압、공제혈당、방치병발증등처리；치료조재상규치료기출상급여의체랍봉30 mg정맥적주，매천2차，공14 d。2조재치료전후진행구주졸중평분( ESS )、일상생활능력평분( ADL)，판단기료효，관찰기유무불량반응。결과：치료조치료후7 d、14 d화21 d ESS화ADL평분균명현고우대조조( P<0.01)，치료조치료후14 d화21 d총유효솔균고우대조조(P<0.01)，차무엄중불량반응。결론：의체랍봉가유효치료뇌간출혈병개선예후，안전성량호。
Objective:To evaluate effect and safety of edaravone on patients with brain stem hemorrhage. Methods:Forty patients with brain stem hemorrhage were devided into edaravone group(n=20) and control group(n=20). Cases of edaravone group were infused at a dose 30 mg twice a day for 14 days. The measures of osmotic diuretics,antihypertensives,antidiabetics and prevention complication were executed in the control group. The European stroke scale( ESS) and activities of daily living( ADL) were evaluated before and after treatment for judging effect and side effect. Results:There were significant differences between edaravone group and control group in ESS and ADL(P<0. 01). The efficiency in treatment group was significantly higher than that in control group(P<0. 01)and without complications. Conclusions:Edarvone is effective and safe drug in treating patients with acute brain stem hamorrage.